Europe's biotechs have always held their own when it comes to scientific innovation but despite the tricky climate for financing, there are plenty of firms that have the potential to go from discovery to late-stage development and even commercialization.
That is the view of Sofia Ioannidou and Olivier Litzka, two of the five partners (along with Gilles Nobécourt, Jan...






